ERBB2 and gastric cancer: In addition, although zolbetuximab is currently approved only for use with chemotherapy in patients with HER2-negative advanced GC, combination strategies pairing zolbetuximab with immunotherapies are in development and may offer a promising approach to overcoming early treatment resistance.